Clinical outcomes and safety of efgartigimod in Guillain–Barré syndrome: a retrospective observation study - Takeaways - MDSpire

Clinical outcomes and safety of efgartigimod in Guillain–Barré syndrome: a retrospective observation study

  • By

  • Yongli Tao

  • Ting Yang

  • Chenyang Jiang Jiang

  • Xue Wang

  • Liangliang Gu

  • Rui Zhang

  • June 19, 2026

  • 0 min

Share

  • 1

    Efgartigimod is a human IgG antibody Fc fragment that may enhance IgG degradation, presenting a potential treatment for Guillain–Barré syndrome (GBS).

  • 2

    In a retrospective study, 52 GBS patients received either IVIg, efgartigimod, or IVIg sequential efgartigimod (ISE) between February 2024 and June 2025.

  • 3

    The efgartigimod group showed a higher proportion of good improvement at week 2 and the final visit compared to the IVIg group.

  • 4

    The incidence of treatment-related adverse events was lower in the efgartigimod group (18.8%) compared to the IVIg (50.0%) and ISE (43.8%) groups.

  • 5

    The study suggests efgartigimod may be effective and safe for GBS, but acknowledges methodological limitations and the need for larger trials.

Original Source(s)

Clinical outcomes and safety of efgartigimod in Guillain–Barré syndrome: a retrospective observation study

  • by Yongli Tao, Ting Yang, Chenyang Jiang Jiang, Xue Wang, Liangliang Gu, Rui Zhang

  • June 19, 2026

Related Content

Cognitive impairment and prefrontal TGF-β1 elevation in a rat model of fatigue

Identification of genes associated with cervical intervertebral disc degeneration and immune cell infiltration

Case Report: Hybrid retrograde transcarotid stenting for common carotid artery dissection secondary to acute type A aortic dissection